ImmunityBio released FY2025 Semi-Annual earnings on August 5 (EST), actual revenue USD 42.94 M, actual EPS USD -0.26

Brief Summary

ImmunityBio’s 2025 half-year revenue was $42.94 million with an EPS of -$0.26.

Impact of The News

ImmunityBio reported a half-year revenue of $42.94 million and an EPS of -$0.26, which indicates a challenging financial period. The company’s revenue exceeded the market consensus of $24.05 million for Q2, achieving $26.43 million, demonstrating a significant improvement in sales, primarily driven by a 246% increase in Anktiva unit sales compared to the second half of 2024 Reuters+ 3. Despite the improvement in revenue, the company still faced a considerable net loss of $222.201 million, although this represents a reduction compared to the previous year’s loss of $268.7 million Reuters+ 2. ImmunityBio’s financial performance includes reduced sales, general, and administrative expenses, which decreased by $16.1 million to $75 million compared to the same period in 2024 LB filings. This cost containment could potentially improve profitability if revenue growth continues. However, the company needs to address the ongoing net losses and work towards achieving a positive EPS. The significant cash reserve of $153.7 million, including cash, cash equivalents, and marketable securities, provides a buffer to support continued operations and potential strategic investments Reuters. Overall, while the company shows signs of revenue growth and cost management, achieving sustained profitability remains a critical challenge.